Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company specializing in cancer drug development, is set to participate in the Q3 Investor Summit on August 20th, 2024. The event, focused on 50 micro-cap companies with catalysts or strong market performance, will feature Lixte's presentation at 2:00 pm ET.
Investors can access the presentation via a live webcast. Throughout the day, Lixte will also be available for one-on-one meetings with interested parties. This summit provides an opportunity for qualified investors to engage with promising micro-cap companies, offering live Q&A sessions and in-depth discussions.
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), una società biofarmaceutica in fase clinica specializzata nello sviluppo di farmaci contro il cancro, parteciperà al Q3 Investor Summit il 20 agosto 2024. L'evento, focalizzato su 50 aziende micro-cap con catalizzatori o prestazioni di mercato solide, prevede la presentazione di Lixte alle 14:00 ET.
Gli investitori possono accedere alla presentazione tramite un webcast dal vivo. Durante l'intera giornata, Lixte sarà anche disponibile per incontri one-on-one con le parti interessate. Questo summit offre un'opportunità per investitori qualificati di interagire con aziende micro-cap promettenti, offrendo sessioni di domande e risposte dal vivo e discussioni approfondite.
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), una compañía farmacéutica en etapa clínica especializada en el desarrollo de medicamentos contra el cáncer, participará en el Q3 Investor Summit el 20 de agosto de 2024. El evento, centrado en 50 empresas micro-cap con catalizadores o sólido rendimiento en el mercado, presentará a Lixte a las 2:00 p.m. ET.
Los inversores pueden acceder a la presentación a través de un webcast en vivo. Durante todo el día, Lixte también estará disponible para reuniones uno a uno con partes interesadas. Este summit ofrece una oportunidad para que inversores calificados se relacionen con empresas micro-cap prometedoras, ofreciendo sesiones de preguntas y respuestas en vivo y discusiones en profundidad.
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT)는 암 치료제 개발에 특화된 임상 단계의 제약 회사로서 2024년 8월 20일에 3분기 투자자 서밋에 참여할 예정입니다. 이 행사에서는 촉매나 강력한 시장 성과를 가진 50개의 마이크로 캡 기업에 초점을 두고 있으며, Lixte의 발표는 오후 2시 ET에 진행될 예정입니다.
투자자는 라이브 웹캐스트를 통해 발표에 접근할 수 있습니다. 하루 동안 Lixte는 관심 있는 당사자들과 일대일 미팅을 위해 이용 가능합니다. 이 서밋은 적격 투자자들에게 유망한 마이크로 캡 회사들과 교류할 기회를 제공하며, 라이브 Q&A 세션과 심도 있는 논의를 제공합니다.
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), une entreprise pharmaceutique en phase clinique spécialisée dans le développement de médicaments contre le cancer, participera au Q3 Investor Summit le 20 août 2024. L'événement, axé sur 50 entreprises micro-cap avec des catalyseurs ou une forte performance sur le marché, comprendra la présentation de Lixte à 14h00 ET.
Les investisseurs peuvent accéder à la présentation via un webinaire en direct. Tout au long de la journée, Lixte sera également disponible pour des réunions individuelles avec des parties intéressées. Ce sommet offre aux investisseurs qualifiés la possibilité d'interagir avec des entreprises micro-cap prometteuses, avec des sessions de questions-réponses en direct et des discussions approfondies.
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Krebsmedikamenten spezialisiert hat, wird am 20. August 2024 am Q3 Investor Summit teilnehmen. Die Veranstaltung, die sich auf 50 Mikro-Cap-Unternehmen mit Katalysatoren oder starker Marktleistung konzentriert, wird Lixte's Präsentation um 14:00 Uhr ET beinhalten.
Investoren können über ein Live-Webcast auf die Präsentation zugreifen. Den ganzen Tag über wird Lixte auch für Einzelgespräche mit interessierten Parteien zur Verfügung stehen. Dieser Gipfel bietet qualifizierten Investoren die Möglichkeit, mit vielversprechenden Mikro-Cap-Unternehmen in Kontakt zu treten und Live-Q&A-Sitzungen sowie ausführliche Diskussionen anzubieten.
- None.
- None.
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
Event: Q3 Investor Summit
Date: August 20th, 2024
Presentation Time: 2:00 pm ET
Location: https://www.webcaster4.com/Webcast/Page/3062/51117
The theme is 50 micro-cap companies with a catalyst and/or strong performance in the current market.
Take a deep dive with the best Investors in MicroCap
Live Q & A
Complimentary to Qualified Investors. Please REGISTER HERE.
About the Investor Summit
The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Founded in 2015.
Contact:
Fred Rockwell
fred@investorsummitgroup.com
Investor Summit Group
SOURCE: Lixte Biotechnology Holdings, Inc.
View the original press release on accesswire.com
FAQ
When is Lixte Biotechnology Holdings (LIXT) presenting at the Q3 Investor Summit?
What is the focus of Lixte Biotechnology Holdings (LIXT)?
How can investors access Lixte Biotechnology's (LIXT) presentation at the Q3 Investor Summit?
Will Lixte Biotechnology (LIXT) be available for one-on-one meetings at the Q3 Investor Summit?
What is the theme of the Q3 Investor Summit featuring Lixte Biotechnology (LIXT)?
